T. Crockett
Fundador en KalVista Pharmaceuticals Ltd. .
Fortuna: 2 M $ al 30/04/2024
Cargos activos de T. Crockett
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Director/Miembro de la Junta | 01/04/2010 | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Director/Miembro de la Junta | 01/01/2011 | - |
Director Ejecutivo | 01/01/2011 | - | |
Fundador | 01/01/2011 | - |
Historial de carrera de T. Crockett
Antiguos cargos conocidos de T. Crockett.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 21/11/2016 | 06/03/2024 |
Director Ejecutivo | 21/11/2016 | 06/03/2024 | |
Fundador | 26/03/2004 | 06/03/2024 | |
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Corporate Officer/Principal | 01/08/1999 | - |
Formación de T. Crockett.
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Harvard Business School | Undergraduate Degree |
University of Utah | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Reino Unido | 3 |
Operativa
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Founder | 2 |
Sectorial
Health Technology | 4 |
Consumer Services | 4 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- T. Crockett
- Experiencia